

ATROPHIC RHINITIS OF SWINE

SUMMARY

Description and importance of disease: Atrophic rhinitis is an infectious disease of swine characterised by serous to mucopurulent nasal discharge, shortening or twisting of the snout, atrophy of the turbinate (conchal) bones and reduced productivity. It may occur enzootically or more sporadically, depending on a variety of factors including herd immunity. The most severe progressive form is caused by infection with toxigenic strains of *Pasteurella multocida* alone or in combination with *Bordetella bronchiseptica*. Infections with *B. bronchiseptica* alone can cause a mild to moderate form with nonprogressive turbinate bone atrophy. Turbinate atrophy may only be obvious at slaughter or may be detected in the live animal by use of radiography or tomography. Environmental and management factors also contribute to the severity and incidence of this disease. A large proportion of apparently normal pig herds may be infected with *B. bronchiseptica* or nontoxigenic *P. multocida* and show a mild degree or low prevalence of turbinate atrophy.

Identification of the agents: The diagnosis of atrophic rhinitis depends on clinical and post-mortem observations in affected swine assisted by the recovery and characterisation of *P. multocida* and *B. bronchiseptica*. The isolation of both organisms is often complicated by the more profuse growth of other bacteria. Isolation rates are improved by preservation of the nasal or tonsillar swab at 4–8°C in a non-nutritive transport medium and by using a selective culture medium.

Pasteurella multocida and *B. bronchiseptica* can be identified by traditional biochemical tests. *Pasteurella multocida* isolates may be further characterised by their capsular and somatic antigens. Capsular type D is most prevalent in many areas of the world, but in some regions type A predominates. Capsular antigens may be distinguished serologically by indirect haemagglutination or immunofluorescence, chemically by flocculation in acriflavine, or by susceptibility to hyaluronidase. Somatic antigen types can be distinguished by a gel diffusion precipitation test, with type 3 found most frequently in swine. Toxigenicity of *P. multocida* isolates can be demonstrated by testing for cytotoxicity in cultured cells or with a commercially available toxin-specific enzyme-linked immunosorbent assay (ELISA). The ELISA is also suitable for detection of toxin production by bacteria from primary culture plates without the need for prior isolation and identification of individual colonies.

Assays based on the use of conventional or real-time polymerase chain reaction (PCR) provide rapid, sensitive and highly specific detection of *B. bronchiseptica* and both toxigenic and nontoxigenic *P. multocida* for those laboratories with the capability to perform them. A multiplex PCR useful for capsular typing of *P. multocida* has also been described.

Serological tests: Detection of antibodies to *P. multocida* and *B. bronchiseptica* is of little value as nontoxigenic strains of *P. multocida* share cross-reactive antigens with toxigenic strains and *B. bronchiseptica* can be isolated from many swine herds. ELISAs for detection of antibodies to the *P. multocida* toxin have been described but their usefulness is limited as not all infected swine develop such antibodies. Widespread vaccination with *P. multocida* toxoid induces antibodies of vaccinal origin, complicating interpretation of results.

Requirements for vaccines: Several vaccines are available commercially that contain bacterins of *B. bronchiseptica* and a mixture of toxigenic and/or nontoxigenic strains of *P. multocida*, or a toxoid derived from *P. multocida* or from a recombinant *Escherichia coli*.

A. INTRODUCTION

1. Description and impact of the disease

Initial clinical signs include sneezing, snuffling and eye discharge with resultant dark tear-staining and subsequent nasal discharge, which can vary from serous to mucopurulent; in some cases pigs may show epistaxis. Atrophy of the nasal turbinate and septal deviation may lead to shortening or twisting of the snout and, in severe cases, difficulty in eating. Increased severity is associated with overstocking and poor management, housing and environmental conditions. Reduced productivity is generally associated with moderate to severe atrophic rhinitis, although the precise relationship between infection with the causative bacteria and reduced weight gains has not been thoroughly elucidated.

Bordetella bronchiseptica or toxigenic *P. multocida* may be present in a herd without clinical evidence of disease, especially when other respiratory pathogens are absent and environmental and management conditions are optimal. Such carrier herds pose a risk of transmitting these agents to other herds in which progression to severe disease may occur. *Bordetella bronchiseptica* and toxigenic *P. multocida* are commonly found in many domesticated and wild animal species that could potentially transmit the bacteria to swine herds.

2. Nature and classification of the pathogens

Atrophic rhinitis is an infectious disease of swine characterised by stunted development or deformation of the nasal turbinate (conchal bone) and septum.

Two forms of atrophic rhinitis have been recognised, depending on the causal agent(s) (Brockmeier *et al.*, 2012):

- i) A severe progressive form caused by toxigenic isolates of *Pasteurella multocida*, most commonly capsular types D or A, alone or in combination with *Bordetella bronchiseptica*.
- ii) A less severe, nonprogressive form with mild to moderate turbinate atrophy, often without significant snout changes, caused by *B. bronchiseptica*.

3. Zoonotic potential and biosafety and biosecurity requirements

Infection of humans by *B. bronchiseptica* is rare and occurs most often in immunocompromised persons exposed to infected or vaccinated pets; transmission from swine to humans has not been reported. *Pasteurella multocida* can be a serious human pathogen but most zoonotic infections are associated with exposure to pets or wild animals. *Pasteurella multocida* has also been frequently isolated from healthy human carriers working in swine production sites or living nearby and has sometimes been associated with chronic or acute disease in such individuals (Donnio *et al.*, 1999; López *et al.*, 2013; Marois *et al.*, 2009). Transmission occurs primarily through bites or scratches and wound contamination from infected material, but may also result from inhalation of aerosols. Appropriate precautions should be observed by persons having contact with swine infected with *P. multocida*, particularly those who may be immunocompromised. Clinical specimens and cultures of *B. bronchiseptica* and *P. multocida* should be handled with appropriate biosafety and containment procedures as determined by biorisk analysis (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*).

4. Differential diagnosis

Porcine cytomegalovirus also causes rhinitis in young pigs but does not progress to turbinate atrophy or nasal distortion. Asymmetric bone development resulting from habitual biting or chewing of stalls or drinkers may lead to a noticeable misalignment of the jaw in some pigs. Careful inspection can distinguish this condition from shortness or deviation of the snout characteristic of atrophic rhinitis.

B. DIAGNOSTIC TECHNIQUES

Table 1. Test methods available for the diagnosis of atrophic rhinitis of swine and their purpose

Method	Purpose					
	Population freedom from infection	Individual animal freedom from infection prior to movement	Contribute to eradication policies	Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination
Identification of the agent ^(a)						
Culture and biochemical testing	+++	+++	+++	+++	+++	–
Real-time PCR	++	++	++	++	++	–
Conventional PCR	++	++	++	++	++	–
ELISA for <i>P. multocida</i> toxin	++	++	++	++	++	–
CPE for <i>P. multocida</i> toxin	+	+	+	+	+	–
Detection of immune response						
ELISA for <i>P. multocida</i> toxin	–	–	–	–	–	++
ELISA or agglutination testing for <i>B. bronchiseptica</i>	++	++	n/a	++	++	++

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

PCR = polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay; CPE = cytopathic effect in tissue culture.

^(a)A combination of agent identification methods applied on the same clinical sample is recommended.

The diagnosis of atrophic rhinitis depends on clinical, pathological and microbiological investigations, with the latter being particularly important for herds infected subclinically. It is generally accepted that a herd in which toxigenic *P. multocida* is present be defined as affected with progressive atrophic rhinitis, whether or not clinical signs of the disease are evident (Pedersen *et al.*, 1988). Control in many countries has, therefore, centred on detection of infection, even in subclinically infected animals considered to be potential carriers.

1. Pathological diagnostic criteria

Turbinates may only be seen at slaughter when snout sections at the level of the first/second premolar tooth are examined. Subjective assessment of turbinate atrophy is convenient and often useful for monitoring herds (Brockmeier *et al.*, 2012), but objective scales of measurement (Gatlin *et al.*, 1996) are best suited for studies requiring data analysis. Radiography (Done, 1976) and tomography (Magyar *et al.*, 2013) can provide objective observations from live animals; tomography reveals not only severe lesions but more subtle changes that may not be apparent by radiography. However, these techniques are of limited use due to the equipment and expertise required. Diagnosis is assisted by detection of characteristic histopathological features including fibrous

replacement of the bony plates of the ventral conchae with varying degrees of inflammatory and reparative changes.

2. Identification of the agents

2.1. *In vitro* culture

As *P. multocida* preferentially colonises the tonsil, tonsillar swabs or biopsies will provide the highest isolation rates (Ackermann *et al.*, 1994). Nasal swabs are preferred for isolation of *B. bronchiseptica*. When sampling the tonsil is not practical, nasal swabs suffice for isolation of both organisms. Swabs with flexible shafts should be used; sample collection in young pigs is facilitated by the use of mini-tipped swabs. A single swab is used to sample both sides of the nasal cavity and should then be placed in a non-nutritive transport medium (e.g. phosphate buffered saline) and kept at 4–8°C during transit to avoid overgrowth by other faster-growing bacteria. Transit time should not exceed 24 hours.

Although both *P. multocida* and *B. bronchiseptica* grow readily on blood agar, a selective medium is preferred as overgrowth of other bacteria that are present in higher numbers often interferes with their detection. An additional difficulty related to *B. bronchiseptica* is that this organism grows more slowly than most other bacteria present in clinical samples. Various formulations of media containing antibiotics have been used for isolation of *P. multocida*, but comparison of studies in the literature indicates that the highest isolation rates are obtained with modified Knight medium (bovine blood agar containing 5 µg/ml clindamycin, 0.75 µg/ml gentamicin) (Lariviere *et al.*, 1993) or KPMD (bovine blood agar containing 3.75 U/ml bacitracin, 5 µg/ml clindamycin, 0.75 µg/ml gentamicin, and 2.25 µg/ml amphotericin B) (Ackermann *et al.*, 1994). MacConkey agar with 1% glucose and 20 µg/ml furaltadone is used by many laboratories for selective growth of *B. bronchiseptica* from nasal swabs, but a modified Smith-Baskerville medium (a peptone agar formulation containing 20 µg/ml penicillin, 20 µg/ml furaltadone, and 0.5 µg/ml gentamicin) appears superior, especially when the number of *B. bronchiseptica* present is low (Lariviere *et al.*, 1993; Smith & Baskerville, 1979). A further improvement in isolation rate was reported using blood agar containing 40 µg/ml cephalexin (Lariviere *et al.*, 1993). A selective blood agar medium for simultaneous isolation of both *P. multocida* and *B. bronchiseptica*, containing 5 mg/litre clindamycin-HCl, 0.75 mg/litre gentamicin sulphate, 2.5 mg/litre K-tellurite, 5 mg/litre amphotericin-B and 15 mg/litre bacitracin, has also been described (De Jong & Borst, 1985). However, it should be noted that K-tellurite has sometimes been found to be inhibitory to the growth of type D *P. multocida* (Lariviere *et al.*, 1993).

2.2. Biochemical characteristics

Pasteurella multocida is a Gram-negative, bipolar, pleomorphic rod and forms nonhaemolytic, greyish colonies on blood agar with a characteristic, 'sweetish' odour. It fails to grow on MacConkey agar but yields positive oxidase and catalase reactions and produces indole.

Bordetella bronchiseptica is also a Gram-negative rod, forming convex colonies 1–2 mm in size, usually haemolytic, on blood agar or Bordet-Gengou medium after 48 hours of growth. It is nonfermentative, but positive for oxidase, catalase, citrate and urea and grows in 6.5% NaCl.

Agglutination tests using specific antisera have been described for confirming the identity of presumptive *B. bronchiseptica* isolates but appropriate sera are not widely available for use.

2.2.1. Capsular typing of *P. multocida*

Capsular typing of *P. multocida* is useful for epidemiological purposes, as *P. multocida* often has a mucoid capsule. Serotyping by indirect haemagglutination has traditionally been used (Carter, 1955) but only a few laboratories throughout the world make and maintain the antisera required. However, simpler chemical methods can usually distinguish most swine isolates. Those producing a type D capsule form a heavy flocculate in 1/1000 aqueous acriflavine (Carter & Subronto, 1973), while capsular type A strains can be identified by inhibition of growth in the presence of hyaluronidase (Carter & Rundell, 1975). A small proportion of swine isolates are noncapsulated.

2.2.2. Acriflavine test procedure for capsular type D *P. multocida*

- i) Inoculate a tube containing 3 ml of brain–heart infusion broth, using a freshly grown bovine blood agar culture, for each *P. multocida* isolate to be tested. Include a known type D strain and a known type A strain as positive and negative controls.
- ii) Incubate inoculated tubes at 37°C for 18–24 hours.
- iii) Pellet bacteria by centrifugation and remove 2.5 ml of the supernatant.
- iv) Add 0.5 ml of a 1/1000 aqueous solution of acriflavine neutral. Acriflavine solution should be freshly prepared each week and stored at 4°C, protected from light.
- v) Mix to resuspend the bacterial pellet and incubate the tube at room temperature, without shaking.
- vi) Observe at 5 minutes for the presence of a heavy flocculent precipitate.

2.2.3. Hyaluronidase test procedure for capsular type A *P. multocida*

- i) Prepare fresh bovine blood agar cultures of the isolates to be tested. Include a known type A strain and a known type D strain as positive and negative controls.
- ii) Inoculate each strain to be examined on a separate trypticase soy blood agar plate with 5% sheep blood or 6% bovine blood by streaking several parallel lines of growth, approximately 3–5 mm apart, across the diameter of the plate. For maximum production of hyaluronic acid it is important that the plates be fresh and not dehydrated.
- iii) Heavily streak a hyaluronidase-producing strain of *Staphylococcus aureus* at right angles to the lines of *P. multocida* growth.
- iv) Incubate the plates at 37°C, in a humidified atmosphere, and observe periodically for up to 24 hours. Type A strains will exhibit a marked inhibition of growth in the region adjacent to the growth lines of *S. aureus*.

2.2.4. Somatic antigen typing of *P. multocida*

Differences in the cell wall lipopolysaccharide among *P. multocida* strains provide the basis for somatic antigen typing. Sixteen types can be distinguished by a gel diffusion precipitation test (Heddleston *et al.*, 1972), with type 3 found most frequently in swine. Although the required antisera are not widely available, many reference laboratories and some diagnostic laboratories offer somatic antigen typing.

2.2.5. Detection of the *P. multocida* toxin

Diagnosis of progressive atrophic rhinitis depends upon characterisation of *P. multocida* isolates as toxigenic. The heat-labile toxin of *P. multocida* produces dermonecrosis in guinea-pigs and is lethal in mice following intraperitoneal injection. Toxigenicity can also be demonstrated *in vitro* by testing for cytopathic effects on monolayers of embryonic bovine lung (EBL) cells (Rutter & Luther, 1984), African green monkey kidney (Vero) cells (Pennings & Storm, 1984) or bovine turbinate cells (Eamens *et al.*, 1988). The bacteria are grown in brain–heart infusion broth incubated at 37°C for 24 hours and then pelleted by centrifugation. The supernatant is sterilised by filtration and titrated in monolayer cultures prepared in microtitre plates. Following incubation at 37°C for 2–3 days, the monolayers are stained with crystal violet and examined microscopically to detect cytopathic effects. A rapid cell culture test, in which the suspect colonies are grown on an agar overlay of EBL cells (Chanter *et al.*, 1986), permits more efficient analysis of large numbers of isolates.

An enzyme-linked immunosorbent assay (ELISA) for detection of the *P. multocida* toxin, commercially available in some countries, can be used to test mixtures of bacteria recovered from primary isolation media. This is an important advantage as swine may be colonised simultaneously with a mixture of toxigenic and nontoxigenic strains (Ackermann *et al.*, 1994; Brockmeier *et al.*, 2012). Cell culture methods would require every colony of *P. multocida* in the sample to be tested, which is clearly impractical, to achieve the same level of sensitivity as the ELISA. The ELISA is also suitable for use with individual isolates. Though highly specific, a positive result without previous history of disease or suspicious signs should be thoroughly investigated to recover toxigenic isolates from the animals sampled.

2.3. Molecular methods

Colony morphology and biochemical testing remain the basis for identification of toxigenic *P. multocida* and *B. bronchiseptica* in many laboratories. However, assays based on polymerase chain reaction (PCR) for detection of these agents from swine, including conventional PCRs (Kamp *et al.*, 1996; Lichtensteiger *et al.*, 1996; Nagai *et al.*, 1994; Register & DeJong, 2006) and a real-time PCR (Scherrer *et al.*, 2016) provide faster, more specific and more sensitive diagnostic tools. Diagnostic laboratories are increasingly using PCR for identification of these agents as the equipment and expertise become more readily available. Proper in-house validation with known controls as well as standardised, ongoing quality control measures are essential (see Chapter 1.1.6 *Validation of diagnostic assays for infectious diseases of terrestrial animals*).

Nucleotide sequences of primer pairs used by Register & DeJong (2006) for conventional PCR detection of *B. bronchiseptica* and toxigenic *P. multocida*, respectively, written 5' to 3', are:

Fla4: TGG-CGC-CTG-CCC-TAT-C/Fla2: AGG-CTC-CCA-AGA-GAG-AAA-GGC-TT

toxA-7: ACT-ACA-GAT-TCC-TAA-CAA-AGG-TTC-TGG/toxA-6: TGC-TCA-AAT-CCT-AAA-TCA-CCT-TGT

Nucleotide sequences of the primers and probe reported for real-time PCR detection of toxigenic *P. multocida* (Scherrer *et al.*, 2016), written 5' to 3', are:

toxA-F: GAA-ATG-GCT-GGA-AAA-ACC-AGT-G/toxA-R: GAA-AAG-GCG-CTG-AAA-TTA-CTG-TAT-C

toxA-probe: CGG-CTG-ATT-TAA-TAC-GCT-TTG-CCT-TGC

A multiplex PCR assay for capsular typing of *P. multocida* (Townsend *et al.*, 2001) appears to provide more reliable results than phenotypic methods and is frequently used in suitably equipped diagnostic laboratories.

Various DNA fingerprinting or sequence-based typing techniques, including restriction endonuclease analysis (REA), ribotyping, pulsed-field gel electrophoresis, multilocus sequence typing, and PCR-based methods have been evaluated by numerous groups for the purpose of differentiating *P. multocida* isolates. Few direct comparisons between methods have been carried out using strains from pigs with atrophic rhinitis, but REA currently appears to be the method of choice for epidemiologic investigations as it provides a high level of discrimination without the need for specialised equipment or reagents (Djordjevic *et al.*, 1998; Gardner *et al.*, 1994; Harel *et al.*, 1990).

3. Serological tests

At present there are no satisfactory serological tests that can be relied on to detect those animals infected with toxigenic *P. multocida* and capable of developing or spreading the disease. Detection of antibodies to *P. multocida* is not helpful, as nontoxigenic strains share many cross-reacting antigens with toxigenic strains. ELISAs for detection of antibodies to the *P. multocida* toxin have been described (Foged, 1992; Takada-Iwao *et al.*, 2007). However, many animals infected with toxigenic *P. multocida* fail to produce antibodies to the toxin, and widespread use of toxoid-containing vaccines limits the diagnostic value of these ELISAs to herds with no history of vaccination (for which results are definitive only when positive) or to detection of vaccine response in vaccinated herds.

Infection with *B. bronchiseptica* can be detected serologically by agglutination testing with formalin-treated bacteria or with a more sensitive ELISA (Venier *et al.*, 1984). Unless monitoring the status of a negative herd, *B. bronchiseptica* serology may be of little value as the organism is present in many apparently healthy pig herds.

C. REQUIREMENTS FOR VACCINES

1. Background

There are several commercially available vaccines that contain whole-cell bacterins of *B. bronchiseptica* combined with a toxigenic *P. multocida* bacterin and/or a *P. multocida* toxoid. The toxigenic *P. multocida* bacterin component is most often capsular type D but some vaccines additionally include a type A strain, which may be toxigenic or

nontoxicogenic. Live, attenuated *B. bronchiseptica* vaccines are also available. Vaccines containing only *B. bronchiseptica* are not suitable for control of progressive atrophic rhinitis, but may be of benefit in herds with the nonprogressive form. *Pasteurella multocida* and *B. bronchiseptica* vaccines appear to reduce the level of colonisation by these bacteria, but do not eliminate them or prevent infection. Most commercially available vaccines contain either an oil adjuvant or aluminium hydroxide gel.

The *P. multocida* toxin is the single most important protective antigen with respect to progressive atrophic rhinitis. Vaccines based on a *P. multocida* toxoid offer specific protection against the action of the toxin, which, by itself, can be used to reproduce all of the major signs of this disease (see Foged, 1992 for review). The level of toxin produced by *P. multocida* is relatively low and the toxin-specific antibody response induced by bacterin-only vaccines may not be optimal. Purified toxoid (inactivated by formaldehyde) is more immunogenic than crude toxoid and the immunogenicity of the inactivated form is not affected by mixture with a *B. bronchiseptica* bacterin. However, the difficulty and expense of large-scale purification from cultures of *P. multocida* prevent routine incorporation of native, chemically inactivated toxoid into vaccines. Recombinant vaccines containing subunit toxin proteins or genetically detoxified derivatives of the full-length toxin are highly efficacious and less costly to produce (Foged et al., 1992; Hsuan et al., 2009). A DNA vaccine encoding a full-length but enzymatically inactive toxoid was shown to be highly immunogenic in pigs but has so far not been evaluated for efficacy against challenge (Register et al., 2007).

Bordetella bronchiseptica produces a variety of toxins and adhesins that are potential virulence factors in swine. Only one, the outer membrane protein pertactin, has been shown to protect against disease in pigs (Kobisch & Novotny, 1990). Despite this fact, a dermonecrotic toxin produced by *B. bronchiseptica*, unique from the toxin produced by *P. multocida*, has traditionally been regarded as the primary virulence factor and protective immunogen in swine (Brockmeier et al., 2012). Several studies strongly implicate the toxin as a virulence factor and it undoubtedly plays a role in pathogenesis and, perhaps, in protection. However, the role of pertactin and several additional virulence factors in protective immunity is most likely equal to, or perhaps exceeds, that of the toxin.

Bordetella bronchiseptica is subject to phenotypic variation under certain growth conditions (e.g. temperatures below 37°C or the presence of chemical modulators such as MgSO₄ or nicotinic acid), in which production of most virulence factors is reversibly turned off. Spontaneously occurring mutants, permanently unable to produce most virulence factors, also arise with a low frequency during culture. Careful attention to colony morphology, on an area of the plate with well-separated colonies, is essential to retain cultures in the phase I (also known as Bvg⁺), or virulent, mode. Phase I colonies are small (1–2 mm in diameter), domed, and haemolytic on blood agar. Loss of haemolysis and the appearance of larger, flat colonies indicate conversion to the avirulent form. Whenever possible, cultures should be propagated using single haemolytic colonies to minimise the slow accumulation of avirulent clones within the culture.

Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine production*. The guidelines given below and in Chapter 1.1.8 are intended to be general in nature and may be supplemented by national and regional requirements.

2. Outline of production and minimum requirements for vaccines

2.1. Characteristics of the seed

2.1.1. Biological characteristics of the master seed

The seed-lot system should be employed for the bacterial strains used to prepare whole-cell bacterins, as well as for the strains from which purified antigens are derived.

In the case of whole-cell bacterins, the origin and history of both the *P. multocida* and *B. bronchiseptica* strains should be described and the full characterisation of the master seeds should be laid down in a master seed batch protocol. *Bordetella bronchiseptica* used for vaccine production should be a phase I virulent culture and the *P. multocida* isolates used should be toxigenic.

Working seeds used for vaccine production should be derived from the master seed and checked for all relevant properties as described in the master seed batch protocol.

2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

Both the master seed and the working seed must be pure cultures, free from bacterial, mycotic, mycoplasmal and viral contamination. Related guidelines are provided in Chapter 1.1.9 *Tests for sterility and freedom from contamination of biological materials intended for veterinary use*.

Identity of the bacterial species and the production of relevant antigens should be confirmed.

2.2. Method of manufacture

2.2.1. Procedure

Precise details of standards for the production of effective commercial vaccines are not available, but they are known to contain 10^{10} cells of formalin-killed *B. bronchiseptica* and 10 µg of *P. multocida* toxoid per dose. *Bordetella bronchiseptica* should be confirmed to be a phase I culture and, for *P. multocida*, it should be confirmed that the culture contains sufficient levels of toxin. A defined number of passages should be used to give the production culture. *Bordetella bronchiseptica* cells, and either *P. multocida* cells and/or toxin, are inactivated, detoxified and formulated with an adjuvant. As the toxin of *P. multocida* has an intracellular location and is released on cell lysis during the stationary phase, the culture supernatant should be harvested approximately 48 hours after the end of the exponential phase of growth.

2.2.2. Requirements for ingredients

All bacterial strains should be propagated in media that support efficient growth and allow optimal expression of the antigens that are relevant for the induction of protective antibodies.

2.2.3. In-process controls

Seed and production cultures are inoculated on blood agar plates and incubated. No nonspecific colonies should grow on these plates.

Cultures are inactivated with formaldehyde. Tests are performed to check the effectiveness of the inactivation process and to test for residual formaldehyde.

Quantification of antigens is carried out by performing a total cell count using a bacterial counting chamber for enumerating whole cells or an antigenic mass determination for defined antigens, e.g. *P. multocida* toxin, by quantitative enzyme immunoassay.

2.2.4. Final product batch tests

i) Sterility

Every batch of vaccine should be tested for sterility according to standard methods (see chapter 1.1.9) described in the European Pharmacopoeia or the United States Code of Federal Regulations.

ii) Identity

Identity testing should be conducted on every batch of vaccine using standard methods, such as those described in the European Pharmacopoeia or the United States Code of Federal Regulations.

iii) Safety

Every batch of vaccine should be tested for safety in the target animal, by giving a double dose by the recommended route of vaccination, and a second, single dose 2 weeks later. No abnormal local or systemic reactions should occur. When a preservative is used, the concentration should be measured for each batch. It must not exceed the maximum permitted level. Batch-to-batch safety tests are required unless safety of the product is demonstrated and approved in the registration dossier and production is consistent with that described in chapter 1.1.8.

iv) Batch potency

Every batch of vaccine should be tested for potency using a validated serological test that correlates with the protection obtained in the efficacy experiment, as described under Section C.2.3.2. The potency test is not necessarily carried out in the target animal – mice or rabbits can be used. In these latter cases, correlation has to be shown with protective antibody levels in the target animal.

2.3. Requirements for relevant regulatory approval

2.3.1. Manufacturing process

For regulatory authorisation of vaccine, all relevant details concerning manufacture of the vaccine and quality control testing (see Section C.2.1 *Characteristics of the seed* and Section C.2.2 *Method of manufacture*) should be submitted to the authorities. This information shall be provided from three consecutive vaccine batches with a volume not less than 1/3 of the typical industrial batch volume.

2.3.2. Safety requirements

i) Reversion-to-virulence for attenuated/live vaccines and environmental considerations

Attenuating genetic changes in modified live *B. bronchiseptica* vaccines are generally not well-characterised, but reversion to virulence has not been reported. Regulatory approval may require backpassage studies, in which the vaccine is serially passaged in the target animal for a specified number of times, with no evidence of an increase in virulence.

ii) Precautions (hazards)

Although inactivation of the bacterial cultures by a validated method is a standard procedure, both *B. bronchiseptica* and *P. multocida* produce dermonecrotic toxins; detoxification of these toxins should be confirmed when toxoids are used as vaccine components.

When an oil emulsion is used as the adjuvant, accidental injection of the operator can cause a severe local reaction. Medical attention should be sought immediately, treating the wound as a grease-gun injury.

Manufacturers should provide adequate warnings that medical advice should be sought in the case of self-injection with warnings included on the product label/leaflet so that the vaccinator is aware of any danger.

2.3.3. Efficacy requirements

To register a commercial vaccine, a batch or batches produced according to the standard method and containing the minimum amount of antigen or potency value shall prove its efficacy (protection); each future commercial batch shall be tested before release to ensure it has the same potency value demonstrated by the batch(es) used for the efficacy test(s).

Normally the vaccine is applied during the late stage of pregnancy, so that progeny will be protected by the uptake of colostral antibodies. The efficacy of a trial vaccine should be measured by vaccinating groups of pregnant sows. Their progeny should be challenged by virulent cultures of *B. bronchiseptica* and toxin-producing *P. multocida*. Significant protection should be obtained against the clinical signs of the progressive form of atrophic rhinitis, i.e. turbinate atrophy. The clinical signs induced in the controls and vaccinates may be compared according to the scoring system of Done (1976).

2.3.4. Duration of immunity

As part of the relevant regulatory approval procedure, the manufacturer should be required to demonstrate the duration of immunity of a given vaccine by either challenge or alternative test at the end of the claimed period of protection.

When the vaccine may be applied irrespective of the stage of pregnancy, duration of immunity should be at least 6 months, so that booster vaccinations twice a year should maintain effective antibody levels.

2.3.5. Stability

As part of the relevant regulatory approval procedure, the manufacturer should be required to demonstrate the stability of all the vaccine's properties at the end of the claimed shelf-life period. Storage temperature shall be indicated and warnings should be given if product is damaged by freezing or ambient temperature.

Every batch of vaccine should be subjected to an accelerated shelf-life test, which has been correlated with real-time shelf-life testing.

3. Vaccines based on biotechnology

A number of vaccines incorporating enzymatically inert *P. multocida* toxin subunits or whole toxin rendered inactive through mutation have been described and evaluated under experimental conditions. The recombinant proteins are generally expressed in *Escherichia coli* and purified prior to use. At present, only a few vaccines that include recombinant toxin or toxin subunits are commercially available; they may or may not include a *P. multocida* bacterin. Evidence so far suggests such vaccines elicit levels of toxin-specific antibody equal to or greater than those obtained with vaccines containing native, chemically inactivated toxoid.

REFERENCES

- ACKERMANN M.R., DEBEY M.C., REGISTER K.B., LARSON D.J. & KINYON J.M. (1994). Tonsil and turbinate colonization by toxigenic and nontoxigenic strains of *Pasteurella multocida* in conventionally raised swine. *J. Vet. Diagn. Invest.*, **6**, 375–377.
- BROCKMEIER S.L., REGISTER K.B., NICHOLSON T.L & LOVING C.L. (2012). In: Diseases of Swine, Tenth Edition, Zimmerman J.J., Karriker L.A., Ramirez A., Schwartz K.J & Stevenson G.W., eds. John Wiley & Sons, Inc., Ames, Iowa, USA, 670–679.
- CARTER G.R. (1955). Studies on *Pasteurella multocida*. I. A hemagglutination test for the identification of serological types. *Am. J. Vet. Res.*, **16**, 481–484.
- CARTER G.R. & RUNDELL S.W. (1975). Identification of type A strains of *P. multocida* using staphylococcal hyaluronidase. *Vet. Rec.*, **96**, 343.
- CARTER G.R. & SUBRANTO P. (1973). Identification of type D strains of *Pasteurella multocida* with acriflavine. *Am. J. Vet. Res.*, **34**, 293–294.
- CHANTER N., RUTTER J.M. & LUTHER P.D. (1986). Rapid detection of toxigenic *Pasteurella multocida* by an agar overlay method. *Vet. Rec.*, **119**, 629–630.
- DE JONG M.F. & BORST G.H. (1985). Selective medium for the isolation of *P. multocida* and *B. bronchiseptica*. *Vet. Rec.*, **116**, 167.
- DJORDJEVIC S.P., EAMENS G.J., HA H., WALKER M.J. & CHIN J.C. (1998). Demonstration that Australian *Pasteurella multocida* isolates from sporadic outbreaks of porcine pneumonia are non-toxigenic (toxA-) and display heterogeneous DNA restriction endonuclease profiles compared with toxigenic isolates from herds with progressive atrophic rhinitis. *J. Med. Microbiol.*, **47**, 679–688.
- DONE J.T. (1976). Porcine atrophic rhinitis: snout radiography as an aid to diagnosis and detection of the disease. *Vet. Rec.*, **98**, 23–28.
- DONNIO P.Y., ALLARDET-SERVENT A., PERRIN M., ESCANDE F. & AVRIL J.L. (1999). Characterisation of dermonecrotic toxin-producing strains of *Pasteurella multocida* subsp. *multocida* isolated from man and swine. *J. Med. Microbiol.*, **48**, 125–131.

- EAMENS G.J., KIRKLAND P.D., TURNER M.J., GARDNER I.A., WHITE M.P. & HORNITZKY C.L. (1988). Identification of toxigenic *Pasteurella multocida* in atrophic rhinitis of pigs by in vitro characterisation. *Aust. Vet. J.*, **65**, 120–123.
- FOGED N.T. (1992). *Pasteurella multocida* toxin. The characterisation of the toxin and its significance in the diagnosis and prevention of progressive atrophic rhinitis in pigs. *APMIS Suppl.*, **25**, 1–56.
- GARDNER I.A., KASTEN R., EAMENS G.J., SNIPES K.P. & ANDERSON R.J. (1994). Molecular fingerprinting of *Pasteurella multocida* associated with progressive atrophic rhinitis in swine herds. *J. Vet. Diagn. Invest.*, **6**, 442–447.
- GATLIN C.L., JORDAN W.H., SHRYOCK T.R. & SMITH W.C. (1996). The quantitation of turbinate atrophy in pigs to measure the severity of induced atrophic rhinitis. *Can. J. Vet. Res.*, **60**, 121–126.
- HAREL J., COTE S. & JACQUES M. (1990). Restriction endonuclease analysis of porcine *Pasteurella multocida* isolates from Quebec. *Can. J. Vet. Res.*, **54**, 422–426.
- HEDDLESTON K.L., GALLAGHER J.E. & REBERS P.A. (1972). Fowl cholera: gel diffusion precipitation test for serotyping *Pasteurella multocida* from avian species. *Avian Dis.*, **16**, 925–936.
- HSUAN S.-L., LIAO C.-M., HUANG C., WINTON J.R., CHEN Z.-W., LEE W.-C., LIAO J.-W., CHEN T.-H., CHIOU C.-J., YEH K.-S. & CHIEN M.-S. (2009). Efficacy of a novel *Pasteurella multocida* vaccine against progressive atrophic rhinitis of swine. *Vaccine*, **27**, 2923–2929.
- KAMP E.M., BOKKEN G.C., VERMEULEN T.M., DE JONG M.F., BUYS H.E., REEK F.H. & SMITS M.A. (1996). A specific and sensitive PCR assay suitable for large-scale detection of toxigenic *Pasteurella multocida* in nasal and tonsillar swabs specimens of pigs. *J. Vet. Diagn. Invest.*, **8**, 304–309.
- KOBISCH M. & NOVOTNY P. (1990). Identification of a 68 kilodalton outer membrane protein as the major protective antigen of *Bordetella bronchiseptica* by using specific-pathogen-free piglets. *Infect. Immun.*, **58**, 352–357.
- LARIVIERE S., LEBLANC L., MITTAL K.R. & MARTINEAU G.P. (1993). Comparison of isolation methods for the recovery of *Bordetella bronchiseptica* and *Pasteurella multocida* from the nasal cavities of piglets. *J. Clin. Microbiol.*, **31**, 364–367.
- LICHTENSTEIGER C.A., STEENBERGEN S.M., LEE R.M., POLSON D.D. & VIMR E.R. (1996). Direct PCR analysis for toxigenic *Pasteurella multocida*. *J. Clin. Microbiol.*, **34**, 3035–3039.
- LÓPEZ C., SANCHEZ-RUBIO P., BETRÁN A. & TERRÉ R. (2013). *Pasteurella multocida* meningitis caused by contact with pigs. *Braz. J. Microbiol.*, **44**, 473–474.
- MAGYAR T., DONKÓ T., REPA I. & KOVÁCS M. (2013). Regeneration of toxigenic *Pasteurella multocida* induced severe turbinate atrophy in pigs detected by computed tomography. *BMC Vet. Res.*, **9**, 222.
- MAROIS C., FABLET C., GAILLOT O., MORVAN H., MADEC F. & KOBISCH M. (2009). Molecular diversity of porcine and human isolates of *Pasteurella multocida*. *J. Appl. Microbiol.*, **107**, 1830–1836.
- NAGAI S., SOMENO S. & YAGIHASHI T. (1994). Differentiation of toxigenic from nontoxigenic isolates of *Pasteurella multocida* by PCR. *J. Clin. Microbiol.*, **32**, 1004–1010.
- PEDERSEN K.B., NIELSEN J.P., FOGED N.T., ELLING F., NIELSEN N.C. & WILLEBERG P. (1988). Atrophic rhinitis in pigs: proposal for a revised definition. *Vet. Rec.*, **122**, 190–191.
- PENNINGS A.M. & STORM P.K. (1984). A test in vero cell monolayers for toxin production by strains of *Pasteurella multocida* isolated from pigs suspected of having atrophic rhinitis. *Vet. Microbiol.*, **9**, 503–508.
- REGISTER K.B. & DEJONG K.D. (2006). Analytical verification of a multiplex PCR for identification of *Bordetella bronchiseptica* and *Pasteurella multocida* from swine. *Vet. Microbiol.*, **117**, 201–210.
- REGISTER K.B., SACCO R.E. & BROCKMEIER S.L. (2007). Immune response in mice and swine to DNA vaccines derived from the *Pasteurella multocida* toxin gene. *Vaccine*, **25**, 6118–6128.

RUTTER J.M. & LUTHER P.D. (1984). Cell culture assay for toxigenic *Pasteurella multocida* from atrophic rhinitis of pigs. *Vet. Rec.*, **114**, 393–396.

SCHERRER S., FREI D. & WITTENBRINK M.M. (2016). A novel quantitative real-time polymerase chain reaction method for detecting toxigenic *Pasteurella multocida* in nasal swabs from swine. *Acta Vet. Scand.*, **58**, 83.

SMITH I.M. & BASKERVILLE A.J. (1979). A selective medium facilitating the isolation and recognition of *Bordetella bronchiseptica* in pigs. *Res. Vet. Sci.*, **27**, 187–192.

TAKADA-IWAO A., UTO T., MUKAI T., OKADA M., FUTO S. & SHIBATA I. (2007). Evaluation of an indirect enzyme-linked immunosorbent assay (ELISA) using recombinant toxin for detection of antibodies against *Pasteurella multocida* toxin. *J. Vet. Med. Sci.*, **69**, 581–586.

TOWNSEND K.M., BOYCE J.D., CHUNG J.Y., FROST A.J. & ADLER B. (2001). Genetic organization of *Pasteurella multocida* cap loci and development of a multiplex capsular PCR typing system. *J. Clin. Microbiol.*, **39**, 924–929.

VENIER L., ROTHSCHILD M.F. & WARNER C.M. (1984). Measurement of serum antibody in swine vaccinated with *Bordetella bronchiseptica*: comparison of agglutination and enzyme-linked immunosorbent assay methods. *Am. J. Vet. Res.*, **45**, 2634–2636.

*
* *

NB: At the time of publication (2018) there were no WOA Reference Laboratories for atrophic rhinitis of swine (please consult the WOA Web site: <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

NB: FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2018.